Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process

Roofeh, David; Barratt, Shaney; Wells, Athol U.; Kawano-Dourado, Letícia; Tashkin, Donald P.; Strand, Vibeke; Seibold, James R.; Proudman, Susanna; Brown, Kevin K.; Dellaripa, Paul F.; Doyle, Tracy J.; Leonard, Thomas B.; Matteson, Eric L.; Oddis, Chester V.; Solomon, Joshua J.; Sparks, Jeffrey A.; Vassallo, Robert; Maxwell, Lara; Beaton, Dorcas; Christensen, Robin; Townsend, Whitney; Khanna, Dinesh

doi:10.1016/j.semarthrit.2021.08.001

Cited by 7 publications

(4 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Roofeh et al recently evaluated FVC and DLco using the OMERACT Filter 2.1, an evidence-based algorithm used to identify outcome measures that are truthful, feasible, and able to discriminate between groups of interest; they identified FVC to be endorsed for use in the setting of SSc-ILD clinical trials and longitudinal observational studies. DLco was not endorsed based on the working group's vote (70). Lung ultrasound (LUS) and MRI were recently proposed for screening and follow-up in ILD-SSc patients (71).…”

Section: Pulmonary Involvementmentioning

confidence: 99%

Systemic sclerosis: one year in review 2022

Lepri

Orlandi

Battista

et al. 2022

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Pulmonary Involvementmentioning

confidence: 99%

Systemic sclerosis: one year in review 2022

Lepri

Orlandi

Battista

et al. 2022

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

“…15% in DLCO. 113 The same definition was supported by an international panel of SSc-ILD experts from Europe and North America, who also stated that an increase in the extent of ILD on HRCT imaging if present would also be taken into account. 87 There was no agreement on what time period should be used to assess for lung function decline.…”

Section: Disease Progressionmentioning

confidence: 96%

“…175,176 Principles Guiding Treatment Decisions Clinical practice guidelines concerning the therapeutic approach for patients with SSc-ILD are mainly based on consensus intended to serve as a basis for informed and shared decision-making. 82,113,117,177 An official clinical practice guideline of the American Thoracic Society was approved in May 2023 based on a systematic review of the literature and using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. 117 For the treatment of patients with SSc-ILD, the committee (1) recommended the use of MMF; (2) recommended further research into the safety and efficacy of pirfenidone and the combination of pirfenidone plus MMF; and (3) suggested the use of cyclophosphamide, rituximab, tocilizumab, nintedanib, and the combination of nintedanib plus MMF (►Table 4).…”

Section: Lung Transplantationmentioning

confidence: 99%

Interstitial Lung Disease Associated with Systemic Sclerosis

Mismetti,

Si-Mohamed,

Cottin

2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by a tripod combining vasculopathy, fibrosis, and immune-mediated inflammatory processes. The prevalence of interstitial lung disease (ILD) in SSc varies according to the methods used to detect it, ranging from 25 to 95%. The fibrotic and vascular pulmonary manifestations of SSc, particularly ILD, are the main causes of morbidity and mortality, contributing to 35% of deaths. Although early trials were conducted with cyclophosphamide, more recent randomized controlled trials have been performed to assess the efficacy and tolerability of several medications, mostly mycophenolate, rituximab, tocilizumab, and nintedanib. Although many uncertainties remain, expert consensus is emerging to optimize the therapeutic management and to provide clinicians with evidence-based clinical practice guidelines for patients with SSc-ILD. This article provides an overview, in the light of the latest advances, of the available evidence for the diagnosis and management of SSc-ILD.

show abstract

“…PFT is an effective follow-up assessment of SSc-ILD. 57 In particular, FVC represents the endorsed instrument for use in both RCTs and observational studies, contrary to DLco which was mostly used as a secondary outcome and not always showing positive results. Although DLco is less specific than FVC in identifying pure parenchymal disease changes and it is still part of both definitions of "ILD progression", it might reflect other concomitant changes such as anemia, vasculopathy, or emphysema.…”

Section: Pulmonary Function Testingmentioning

confidence: 99%